Adicet Bio, Inc. (ACET) — 8-K Filings

8-K Filings (27)

• Adicet Bio Files 8-K for Bylaw Amendments & Fiscal Year Change — Dec 29, 2025 Risk: low
  On December 26, 2025, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns amendments to its articles of incorporation or bylaws, a change in its
• Adicet Bio Files 8-K on Security Holder Vote — Dec 19, 2025 Risk: low
  On December 19, 2025, Adicet Bio, Inc. filed an 8-K report. The filing indicates that the company is submitting matters to a vote of its security holders. No sp
• Adicet Bio, Inc. Relocates Principal Executive Offices — Oct 7, 2025 Risk: low
  On October 7, 2025, Adicet Bio, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 131 Dartmouth Street, Fl
• Adicet Bio Files 8-K on Exit Costs — Jul 23, 2025 Risk: medium
  On July 22, 2025, Adicet Bio, Inc. filed an 8-K report detailing cost associated with exit or disposal activities. The filing also included other events and fin
• Adicet Bio Reports on Shareholder Vote — Jun 13, 2025 Risk: low
  Adicet Bio, Inc. filed an 8-K on June 13, 2025, reporting on a matter submitted to a vote of security holders on June 11, 2025. The filing does not disclose the
• Adicet Bio Announces Board Changes and Executive Compensation Updates — Apr 17, 2025 Risk: low
  On April 14, 2025, Adicet Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation arrangements. The filing includes
• Adicet Bio Faces Delisting Concerns — Apr 11, 2025 Risk: high
  Adicet Bio, Inc. filed an 8-K on April 11, 2025, reporting a notice of delisting or failure to satisfy a continued listing rule or standard, with the earliest e
• Adicet Bio, Inc. Relocates Principal Executive Offices — Feb 5, 2025 Risk: low
  On February 5, 2025, Adicet Bio, Inc. filed an 8-K report. The filing indicates a change in the company's principal executive offices to 131 Dartmouth Street, F
• Adicet Bio Files 8-K Report — Dec 19, 2024 Risk: low
  On December 19, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regul
• Adicet Bio Terminates Regeneron Deal — Nov 27, 2024 Risk: medium
  Adicet Bio, Inc. announced on November 27, 2024, the termination of its material definitive agreement with Regeneron Pharmaceuticals, Inc. This termination rela
• Adicet Bio Files 8-K Report — Nov 18, 2024 Risk: low
  On November 18, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regul
• Adicet Bio, Inc. Enters Material Definitive Agreement — Nov 15, 2024 Risk: medium
  On November 8, 2024, Adicet Bio, Inc. entered into a Material Definitive Agreement. The company, formerly known as resTORbio, Inc., is incorporated in Delaware
• Adicet Bio Files 8-K Report — Oct 16, 2024 Risk: low
  On October 16, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regula
• Adicet Bio Files 8-K: Financial Statements & Exhibits — Sep 30, 2024 Risk: low
  On September 30, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, indicating a routine update rather
• Adicet Bio Files 8-K Report — Sep 19, 2024 Risk: low
  On September 19, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily serves as a notification of other events and includes financial statements and
• Adicet Bio Appoints New Chief Medical Officer — Sep 10, 2024 Risk: medium
  On September 10, 2024, Adicet Bio, Inc. announced the appointment of Dr. Steven T. Rosen as Chief Medical Officer. Dr. Rosen brings extensive experience in onco
• Adicet Bio Announces Board Changes and Executive Compensation Updates — Aug 19, 2024 Risk: low
  On August 15, 2024, Adicet Bio, Inc. filed an 8-K report detailing changes in its board of directors and executive compensation. The filing includes the electio
• Adicet Bio Files 8-K Report — Jul 8, 2024 Risk: low
  On July 8, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD disclosures and financial statements/exhibits. No specific ma
• Adicet Bio Files 8-K Report — Jun 24, 2024 Risk: low
  On June 24, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulatio
• Adicet Bio Adds Directors, Amends Bylaws — Jun 7, 2024 Risk: low
  On June 5, 2024, Adicet Bio, Inc. filed an 8-K report detailing several key events. The company announced the election of Dr. Steven J. Altschuler and Ms. Laura
• Adicet Bio Files 8-K — Jun 5, 2024 Risk: low
  Adicet Bio, Inc. filed an 8-K on June 5, 2024, to report on a Regulation FD Disclosure and Financial Statements and Exhibits. The filing does not contain specif
• Adicet Bio Files 8-K for Reg FD and Financials — May 10, 2024 Risk: low
  On May 10, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. The company
• Adicet Bio Files 8-K Report — Apr 22, 2024 Risk: low
  On April 22, 2024, Adicet Bio, Inc. filed an 8-K report. The filing primarily concerns financial statements and exhibits, along with other events and a Regulati
• Adicet Bio, Inc. Files 8-K for Material Agreement — Mar 22, 2024 Risk: medium
  On March 22, 2024, Adicet Bio, Inc. entered into a Material Definitive Agreement. The filing also includes financial statements and exhibits. The company's prin
• Adicet Bio Files 8-K on Material Agreement, Financial Condition — Jan 24, 2024
  Adicet Bio, Inc. filed an 8-K on January 24, 2024, reporting an event that occurred on January 22, 2024. This filing indicates an entry into a material definiti
• Adicet Bio Files Routine 8-K, Confirms Nasdaq Listing — Jan 16, 2024
  Adicet Bio, Inc. filed an 8-K on January 16, 2024, primarily to disclose general corporate information and confirm its status as a publicly traded company on Th
• Adicet Bio Updates Corporate Address, Phone in 8-K Filing — Jan 4, 2024
  Adicet Bio, Inc. filed an 8-K on January 4, 2024, to update its corporate information, including its business address to 200 Berkeley Street, 19th Floor, Boston

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX